ADMdx’s CEO, Dawn Matthews, will be an invited panel speaker at the Alzheimer’s Drug Discovery Foundation (ADDF)’s upcoming Therapeutic Investigator Day on October 23, 2023. This symposium will be held in conjunction with the Clinical Trials for Alzheimer’s Disease (CTAD) conference in Boston, MA. Ms. Matthews’ talk will focus on the role of biomarkers in the development of new treatments to slow and prevent Alzheimer’s disease. She will discuss ADMdx’s work with imaging biomarkers and AI, which has included diagnostic product development and clinical trials sponsored by the ADDF.